<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573950</url>
  </required_header>
  <id_info>
    <org_study_id>cilostaar</org_study_id>
    <nct_id>NCT00573950</nct_id>
  </id_info>
  <brief_title>Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness</brief_title>
  <official_title>Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication.
      Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and
      inhibitor of platelet aggregation. Recently there were report of beneficial effect of
      cilostazol like vasodilation, lipid metabolism, and cytokine production. But there were few
      clinical studies that support these effects of cilostazol. The purpose of this study is to
      evaluate the vasodilatory and anti-inflammatory effect of cilostazol presented by PWV and
      plasma adipocytokines.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect on pulse wave velocity (PWV)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effect on atherosclerotic and inflammatory markers such as adiponectin, hsCRP</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Eligible for study: 18 year and above, Gender eligible for study: both Inclusion
             Criteria:Type 2 diabetes patients with metabolic syndrome criteria of Asian-Pacific
             ATP III guideline

          -  Type 2 diabetes (at least 1 criteria below)

               1. fasting blood glucose ≥ 126 mg/dL

               2. postprandial 2hour glucose ≥ 200 mg/dL

               3. random blood glucose ≥ 200 mg/dL with typical diabetes symptoms

          -  Metabolic syndrome : Asian-Pacific ATP III guideline

               1. Fasting blood glucose ≥ 110 mg/dL, or previously diagnosed type 2 diabetes

               2. systolic and/or diastolic blood pressure ≥130/85 mmHg, or treatment of previously
                  diagnosed hypertension

               3. Triglyceride ≥ 150 mg/dL, or Specific treatment for this lipid abnormality

               4. HDL-cholesterol &lt; 40 mg/dL for men and &lt; 50 mg/dL for women, or Specific
                  treatment for this lipid abnormality

               5. Waist circumference ≥ 90 for men and ≥ 80 for women

        Exclusion Criteria:

          -  Hypertensive patients with the use of ACE inhibitor or ARB

          -  Hyperlipidemic patients with the use of statin or fenofibrate

          -  Hepatic dysfunction

          -  Chronic alcohol or drug abuse

          -  Renal dysfunction

          -  Heart failure

          -  Patients who takes hormone replace therapy or steroid containing drugs

          -  Patients who take drugs like anticoagulant (warfarin), anti-platelet agent (aspirin,
             ticlopidin), thrombolytic agent (urikinase, alteplase), prostaglandine E1 , drugs
             inhibit CYP3A4 or CYP2C19, or drugs become substrate of CYP3A4

          -  Patients who haves disease influencing the results of the study such as neurologic,
             digestive and neoplastic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sin Gon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee Young Kim, MD, PhD</last_name>
    <phone>+82-2-920-5767</phone>
    <email>lynsette@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sin Gon Kim, MD, PhD</last_name>
    <phone>+82-2-920-5767</phone>
    <email>k50367@korea.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea Univerisity Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Kim</last_name>
      <phone>+82-2-920-6566</phone>
      <email>ctcan@kumc.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <last_update_submitted>December 13, 2007</last_update_submitted>
  <last_update_submitted_qc>December 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2007</last_update_posted>
  <responsible_party>
    <name_title>Sin Gon, Kim</name_title>
    <organization>Korea University Anam Hospital</organization>
  </responsible_party>
  <keyword>cilostazol</keyword>
  <keyword>Type 2 Diabetes mellitus</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>adipocytokines</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>Pulse wave velocity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 18, 2011</submitted>
    <returned>May 11, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

